Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Neuropathic pain is a chronic condition caused by damage or dysfunction in the nervous system, leading to burning, tingling, or electric-like pain. As per International Association for the Study of Pain, it affects about 7-10 % of the global population, equating to hundreds of millions of people worldwide. According to the neuropathic pain pipeline analysis by Expert Market Research, current therapies include antidepressants, SNRIs, gabapentinoids, and emerging non-opioid agents, with over 100 novel drugs in development targeting unmet needs. The growing focus on precision medicine, sodium channel modulators, biologics, and innovative delivery methods is expected to expand treatment options and drive substantial growth in the coming years.
-
Major companies involved in the neuropathic pain pipeline analysis include Haisco Pharmaceutical Group Co., Ltd., Sangamo Therapeutics, and others.
-
Leading drugs currently in the pipeline include HSK16149, ST-503, EC5026, and others.
-
The strong clinical momentum is driven by non-opioid mechanisms, rising late-stage assets, and increased focus on disease-modifying targets, supported by unmet need, biomarker-guided development, and expedited regulatory pathways.
Report Coverage
The Neuropathic Pain Pipeline Analysis Report by Expert Market Research gives comprehensive insights into neuropathic pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for neuropathic pain. The neuropathic pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The neuropathic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with neuropathic pain treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to neuropathic pain.
Read more about this report - Request a Free Sample
Neuropathic Pain Pipeline Outlook
Neuropathic pain is a chronic condition caused by damage or dysfunction of the peripheral or central nervous system, leading to abnormal pain signaling. It commonly occurs in conditions like diabetic peripheral neuropathy, lumbosacral radiculopathy, and trigeminal neuralgia, affecting millions worldwide and significantly impacting quality of life.
Neuropathic pain treatments include pharmacological therapies such as anticonvulsants, antidepressants, topical agents, and emerging oral NaV1.8 inhibitors, aimed at reducing abnormal nerve signaling and alleviating persistent pain. In April 2024, Vertex Pharmaceuticals advanced suzetrigine (VX-548) for neuropathic pain, targeting diabetic peripheral neuropathy. Phase 2 studies showed positive outcomes, and the FDA granted Breakthrough Therapy designation. A Phase 3 program is set to initiate in the second half of 2024, aiming to provide a novel non-opioid therapy with improved efficacy and safety profiles for millions of patients suffering from peripheral neuropathic pain.
Neuropathic Pain Epidemiology
The global burden of neuropathic pain is substantial, affecting an estimated 580 to 830 million people worldwide, as highlighted by the International Association for the Study of Pain (IASP) in 2026. According to Williams Fernando Vieira et al., 2024, in North America and Australia, 8-60% of the population experience chronic pain, with approximately 116 million adults in the United States affected, significantly impacting quality of life. Anas Hamdan et al., 2024 estimated that Europe reports a prevalence of 7-8%. In India, diabetic peripheral neuropathy affects up to 50% of individuals with diabetes, with persistent neuropathic pain reported in half of these cases reported by the Kanthed Pravesh et al., 2024.
Neuropathic Pain – Pipeline Therapeutic Assessment
This section of the report covers the analysis of neuropathic pain drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The neuropathic pain pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Neuropathic Pain Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total neuropathic pain clinical trials, at 41%, reflecting strong mid-stage development and potential for future market expansion. Phase I accounts for 21%, indicating ongoing early clinical exploration. Phase III holds 19%, highlighting drugs nearing regulatory approval. Phase IV comprises 15%, supporting post-marketing growth, while early phase I contributes 5%, ensuring a continuous innovation pipeline.
Neuropathic Pain Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the neuropathic pain pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and peptides. The neuropathic pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for neuropathic pain. Small molecule inhibitors are gaining attention in the neuropathic pain market for their targeted mechanism of action. For instance, pilavapadin, a selective AAK1 inhibitor developed by Lexicon Pharmaceuticals, is under Phase 3 investigation for diabetic peripheral neuropathic pain. It modulates neurotransmitter recycling without affecting opioid pathways, offering a promising non-opioid treatment option for patients.
Neuropathic Pain Clinical Trials – Key Players
The EMR report for the neuropathic pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed neuropathic pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in neuropathic pain clinical trials:
- Haisco Pharmaceutical Group Co., Ltd.
- Sangamo Therapeutics
- EicOsis Human Health Inc.
- SIMR Biotechnology Co., Ltd.
- Eli Lilly and Company
- Yidian Pharmaceutical Technology Development Co., Ltd.
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Ono Pharmaceutical Co. Ltd.
- Dogwood Therapeutics Inc.
- Neurodawn Pharmaceutical Co., Ltd.
- Beijing Tide Pharmaceutical Co., Ltd.
- Vertex Pharmaceuticals Incorporated
Neuropathic Pain – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for neuropathic pain. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of neuropathic pain drug candidates.
Drug: HSK16149
HSK16149 is an oral GABA analogue capsule being developed by Haisco Pharmaceutical Group Co., Ltd. for central neuropathic pain. The ongoing Phase III study is evaluating the efficacy and safety of HSK16149 compared with placebo in patients with moderate to severe central neuropathic pain in China. The study examines pain reduction, tolerability, and overall safety outcomes. HSK16149 selectively binds to the α2δ-1 and α2δ-2 subunits of voltage-gated calcium channels, reducing calcium influx in the central nervous system and lowering glutamate and norepinephrine release. The drug is being administered orally at 20–40 mg twice daily.
Genetic: ST-503
ST-503 is an investigational gene therapy being developed by Sangamo Therapeutics for the treatment of refractory neuropathic pain due to small fiber neuropathy (SFN). The Phase 1/2 study is currently recruiting and is examining the safety, tolerability, and preliminary analgesic efficacy of a single intrathecal dose. ST-503 is delivering a modified gene designed to epigenetically repress the Nav1.7 sodium channel, which is playing a key role in transmitting pain signals. By reducing aberrant neuronal signaling, the therapy aims to provide sustained pain relief in patients with chronic, treatment-resistant peripheral neuropathy.
Drug: EC5026
EC5026 is a novel soluble epoxide hydrolase inhibitor (sEHI) being developed as an oral therapy for neuropathic pain in patients with spinal cord injury. Sponsored by EicOsis Human Health Inc., this Phase 1 study examines the safety, tolerability, and pharmacodynamics of multiple daily doses over 14 days. The study aims to determine whether EC5026 is safe and well-tolerated while assessing its effects on pain, sleep, functional status, and patient-reported outcomes. EC5026 works by modulating lipid signaling and inflammatory pathways, offering a non-opioid approach to neuropathic pain management through oral administration.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Neuropathic Pain Pipeline Insight Report
- Which companies/institutions are leading the neuropathic pain drug development?
- Which company is leading the neuropathic pain pipeline development activities?
- What is the current neuropathic pain commercial assessment?
- What are the opportunities and challenges present in the neuropathic pain pipeline landscape?
- What is the efficacy and safety profile of neuropathic pain pipeline drugs?
- Which company is conducting major trials for neuropathic pain drugs?
- Which companies/institutions are involved in neuropathic pain collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in neuropathic pain?
Reasons To Buy This Report
The Neuropathic Pain Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for neuropathic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into neuropathic pain collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Diabetic Neuropathic Pain Market
Diabetic Neuropathic Pain Drug Pipeline Analysis Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share